[{"id":"ce020719-ee60-4c78-aac1-c9da91de0268","acronym":"GIVEN","url":"https://clinicaltrials.gov/study/NCT07472478","created_at":"2026-03-28T01:39:49.899Z","updated_at":"2026-03-28T01:39:49.899Z","phase":"Phase 2","brief_title":"Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)","source_id_and_acronym":"NCT07472478 - GIVEN","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Anfangning (garsorasib) • Yidafan (ivonescimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/15/2026","start_date":" 03/15/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-16"},{"id":"5f6c2565-8588-4402-a34b-b3e63f38e1fa","acronym":"KANDLELIT-014","url":"https://clinicaltrials.gov/study/NCT07209111","created_at":"2025-10-11T01:29:13.435Z","updated_at":"2025-10-11T01:29:13.435Z","phase":"Phase 2","brief_title":"A Clinical Study of MK-1084 in People With Advanced Solid Tumors (MK-1084-014)","source_id_and_acronym":"NCT07209111 - KANDLELIT-014","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/24/2025","start_date":" 11/24/2025","primary_txt":" Primary completion: 04/09/2032","primary_completion_date":" 04/09/2032","study_txt":" Completion: 04/09/2032","study_completion_date":" 04/09/2032","last_update_posted":"2025-10-06"},{"id":"bedbd783-08c6-45af-8549-e837e9ef10ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT07198620","created_at":"2025-10-04T08:02:50.601Z","updated_at":"2025-10-04T08:02:50.601Z","phase":"","brief_title":"A Real-World Study of IBI351 for KRAS G12C+ NSCLC in China","source_id_and_acronym":"NCT07198620","lead_sponsor":"Guangdong Association of Clinical Trials","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Dupert (fulzerasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-09-30"},{"id":"b11c3dd5-a7d2-45b9-88bd-188586703589","acronym":"","url":"https://clinicaltrials.gov/study/NCT07190248","created_at":"2025-09-27T08:39:58.068Z","updated_at":"2025-09-27T08:39:58.068Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","source_id_and_acronym":"NCT07190248","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • KRAS","pipe":"","alterations":" ","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • calderasib (MK-1084)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 675","initiation":"Initiation: 10/27/2025","start_date":" 10/27/2025","primary_txt":" Primary completion: 12/07/2029","primary_completion_date":" 12/07/2029","study_txt":" Completion: 08/06/2032","study_completion_date":" 08/06/2032","last_update_posted":"2025-09-24"},{"id":"eebefa81-1645-4e61-b40b-7636aef12cd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT07012031","created_at":"2025-06-14T13:57:15.769Z","updated_at":"2025-06-14T13:57:15.769Z","phase":"Phase 1/2","brief_title":"Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation","source_id_and_acronym":"NCT07012031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ERBB3","pipe":" | ","alterations":" HER-2 overexpression","tags":["KRAS • ERBB3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 06/06/2025","start_date":" 06/06/2025","primary_txt":" Primary completion: 06/14/2027","primary_completion_date":" 06/14/2027","study_txt":" Completion: 06/14/2027","study_completion_date":" 06/14/2027","last_update_posted":"2025-06-11"},{"id":"ff1be9d1-13a5-4b53-8202-0376c103961f","acronym":"SUNRAY-02","url":"https://clinicaltrials.gov/study/NCT06890598","created_at":"2025-06-07T14:38:17.196Z","updated_at":"2025-06-07T14:38:17.196Z","phase":"Phase 3","brief_title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06890598 - SUNRAY-02","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imfinzi (durvalumab) • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 03/27/2025","start_date":" 03/27/2025","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 02/01/2032","study_completion_date":" 02/01/2032","last_update_posted":"2025-06-05"},{"id":"a81aca55-51bd-4c9d-98b4-44d67b97640e","acronym":"KANDLELIT-012","url":"https://clinicaltrials.gov/study/NCT06997497","created_at":"2025-06-07T14:50:31.299Z","updated_at":"2025-06-07T14:50:31.299Z","phase":"Phase 3","brief_title":"A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)","source_id_and_acronym":"NCT06997497 - KANDLELIT-012","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • calderasib (MK-1084) • levoleucovorin calcium"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 477","initiation":"Initiation: 07/17/2025","start_date":" 07/17/2025","primary_txt":" Primary completion: 08/27/2029","primary_completion_date":" 08/27/2029","study_txt":" Completion: 06/29/2031","study_completion_date":" 06/29/2031","last_update_posted":"2025-05-30"},{"id":"9e8100a2-7197-4a5c-9158-5afa688f8f49","acronym":"PANSOTO","url":"https://clinicaltrials.gov/study/NCT06892054","created_at":"2025-09-07T02:06:33.580Z","updated_at":"2025-09-07T02:06:33.580Z","phase":"Phase 2","brief_title":"Sotorasib Combined with First-line Chemotherapy for Advanced Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT06892054 - PANSOTO","lead_sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • irinotecan"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2025-03-24"},{"id":"2155cc55-44be-403d-a3c7-183b3abe530b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05638295","created_at":"2022-12-06T16:58:31.646Z","updated_at":"2025-02-25T12:29:13.134Z","phase":"Phase 2","brief_title":"Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)","source_id_and_acronym":"NCT05638295","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS","pipe":"","alterations":" ","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"220d0ac1-a83b-4e0c-ba84-1821fcbb0575","acronym":"KRYSTAL 21","url":"https://clinicaltrials.gov/study/NCT05853575","created_at":"2023-05-10T21:04:11.391Z","updated_at":"2025-02-25T12:29:33.318Z","phase":"Phase 2","brief_title":"Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)","source_id_and_acronym":"NCT05853575 - KRYSTAL 21","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/16/2024","start_date":" 02/16/2024","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-24"},{"id":"3c07681e-1c58-4557-8010-1fc74e4cbe8d","acronym":"KRYSTAL-7","url":"https://clinicaltrials.gov/study/NCT04613596","created_at":"2021-01-19T20:33:04.646Z","updated_at":"2025-02-25T12:27:47.978Z","phase":"Phase 2/3","brief_title":"Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7","source_id_and_acronym":"NCT04613596 - KRYSTAL-7","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 806","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 10/31/2028","primary_completion_date":" 10/31/2028","study_txt":" Completion: 10/31/2029","study_completion_date":" 10/31/2029","last_update_posted":"2025-02-24"},{"id":"533b1900-f580-4f57-b6fc-c304162a280a","acronym":"MK-1084-004","url":"https://clinicaltrials.gov/study/NCT06345729","created_at":"2024-04-03T14:39:59.477Z","updated_at":"2025-02-25T12:30:27.021Z","phase":"Phase 3","brief_title":"A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)","source_id_and_acronym":"NCT06345729 - MK-1084-004","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • calderasib (MK-1084)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 05/24/2024","start_date":" 05/24/2024","primary_txt":" Primary completion: 02/19/2029","primary_completion_date":" 02/19/2029","study_txt":" Completion: 02/18/2031","study_completion_date":" 02/18/2031","last_update_posted":"2025-02-24"},{"id":"9816427f-a3a9-4c32-ab07-2e5ae738f6f8","acronym":"KRYSTAL-2","url":"https://clinicaltrials.gov/study/NCT04330664","created_at":"2021-01-18T20:58:21.593Z","updated_at":"2025-02-25T13:40:07.291Z","phase":"Phase 1","brief_title":"Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)","source_id_and_acronym":"NCT04330664 - KRYSTAL-2","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib) • batoprotafib (TNO155)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 86","initiation":"Initiation: 04/07/2020","start_date":" 04/07/2020","primary_txt":" Primary completion: 07/29/2022","primary_completion_date":" 07/29/2022","study_txt":" Completion: 02/24/2025","study_completion_date":" 02/24/2025","last_update_posted":"2025-02-21"},{"id":"f031d34d-933f-4bf9-837f-6a5b73d3ea3f","acronym":"KontRASt-02","url":"https://clinicaltrials.gov/study/NCT05132075","created_at":"2021-11-24T18:55:29.286Z","updated_at":"2025-02-25T13:40:42.926Z","phase":"Phase 3","brief_title":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05132075 - KontRASt-02","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • opnurasib (JDQ443)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 06/23/2022","start_date":" 06/23/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-21"},{"id":"84e74e03-8f34-4176-b63b-03c06eac53aa","acronym":"CodeBreaK 202","url":"https://clinicaltrials.gov/study/NCT05920356","created_at":"2023-06-27T14:08:07.537Z","updated_at":"2025-02-25T13:55:19.667Z","phase":"Phase 3","brief_title":"A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)","source_id_and_acronym":"NCT05920356 - CodeBreaK 202","lead_sponsor":"Amgen","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" PD-L1 expression • PD-L1 negative","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • Lumakras (sotorasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 11/16/2023","start_date":" 11/16/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2031","study_completion_date":" 06/30/2031","last_update_posted":"2025-02-20"},{"id":"8b904991-7019-4cce-9e04-2e7482447f70","acronym":"","url":"https://clinicaltrials.gov/study/NCT05815173","created_at":"2023-04-18T15:04:23.224Z","updated_at":"2025-02-25T14:09:36.744Z","phase":"Phase 1","brief_title":"Ladarixin With Sotorasib in Advanced NSCLC","source_id_and_acronym":"NCT05815173","lead_sponsor":"NYU Langone Health","biomarkers":" KRAS • ALK • RET • ROS1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation","tags":["KRAS • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • ALK rearrangement • KRAS G12 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • ladarixin (DF-2156A)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-19"},{"id":"4e9825d2-8606-4a5c-bf4c-e0714ac9fa73","acronym":"GO42144","url":"https://clinicaltrials.gov/study/NCT04449874","created_at":"2021-01-18T21:24:33.964Z","updated_at":"2025-02-25T14:40:37.769Z","phase":"Phase 1","brief_title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","source_id_and_acronym":"NCT04449874 - GO42144","lead_sponsor":"Genentech, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Tecentriq (atezolizumab) • erlotinib • divarasib (RG6330) • Itovebi (inavolisib) • migoprotafib (RLY-1971)"],"overall_status":"Recruiting","enrollment":" Enrollment 498","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-14"},{"id":"9c9bdd8c-7abe-4b3e-b585-0d05ef9a65f5","acronym":"CodeBreak101","url":"https://clinicaltrials.gov/study/NCT04185883","created_at":"2021-01-18T20:24:19.309Z","updated_at":"2025-02-25T15:11:23.343Z","phase":"Phase 1","brief_title":"Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)","source_id_and_acronym":"NCT04185883 - CodeBreak101","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Mekinist (trametinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Ibrance (palbociclib) • carboplatin • paclitaxel • docetaxel • 5-fluorouracil • everolimus • Vectibix (panitumumab) • Lumakras (sotorasib) • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium • batoprotafib (TNO155) • vociprotafib (RMC-4630) • BI 1701963 • loperamide • zeluvalimab (AMG 404)"],"overall_status":"Recruiting","enrollment":" Enrollment 1200","initiation":"Initiation: 12/17/2019","start_date":" 12/17/2019","primary_txt":" Primary completion: 04/29/2026","primary_completion_date":" 04/29/2026","study_txt":" Completion: 03/13/2028","study_completion_date":" 03/13/2028","last_update_posted":"2025-02-13"},{"id":"482680df-b1a7-4f2f-8588-90fc2e8ec091","acronym":"MK-1084-001","url":"https://clinicaltrials.gov/study/NCT05067283","created_at":"2021-10-05T20:00:06.849Z","updated_at":"2025-02-25T15:19:17.925Z","phase":"Phase 1","brief_title":"A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)","source_id_and_acronym":"NCT05067283 - MK-1084-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • carboplatin • 5-fluorouracil • pemetrexed • oxaliplatin • leucovorin calcium • calderasib (MK-1084)"],"overall_status":"Recruiting","enrollment":" Enrollment 830","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 08/19/2027","primary_completion_date":" 08/19/2027","study_txt":" Completion: 08/19/2027","study_completion_date":" 08/19/2027","last_update_posted":"2025-02-11"},{"id":"91232e9f-dbc4-40d6-b4a1-5da728f867c3","acronym":"KRYSTAL-16","url":"https://clinicaltrials.gov/study/NCT05178888","created_at":"2022-01-05T12:53:44.212Z","updated_at":"2025-02-25T15:27:11.129Z","phase":"Phase 1","brief_title":"Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)","source_id_and_acronym":"NCT05178888 - KRYSTAL-16","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Krazati (adagrasib)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 01/20/2022","start_date":" 01/20/2022","primary_txt":" Primary completion: 06/15/2023","primary_completion_date":" 06/15/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2025-02-11"},{"id":"f1ac3a6c-0328-4766-8476-88308f4d8cc9","acronym":"KRYSTAL-10","url":"https://clinicaltrials.gov/study/NCT04793958","created_at":"2021-03-11T12:53:57.827Z","updated_at":"2025-02-25T15:34:55.257Z","phase":"Phase 3","brief_title":"Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)","source_id_and_acronym":"NCT04793958 - KRYSTAL-10","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Krazati (adagrasib) • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 461","initiation":"Initiation: 06/24/2021","start_date":" 06/24/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-11"},{"id":"75cac4e9-35d9-47ec-8b97-13bc0a811821","acronym":"","url":"https://clinicaltrials.gov/study/NCT06130254","created_at":"2023-11-14T16:14:42.662Z","updated_at":"2025-02-25T14:18:29.119Z","phase":"Phase 1","brief_title":"Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers","source_id_and_acronym":"NCT06130254","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 01/30/2024","start_date":" 01/30/2024","primary_txt":" Primary completion: 08/25/2030","primary_completion_date":" 08/25/2030","study_txt":" Completion: 08/25/2030","study_completion_date":" 08/25/2030","last_update_posted":"2025-02-10"},{"id":"1bd93870-384f-4902-82c2-b2d46a884d55","acronym":"CodeBreak 100","url":"https://clinicaltrials.gov/study/NCT03600883","created_at":"2021-01-17T17:12:15.060Z","updated_at":"2025-02-25T16:31:27.902Z","phase":"Phase 1/2","brief_title":"A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)","source_id_and_acronym":"NCT03600883 - CodeBreak 100","lead_sponsor":"Amgen","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • midazolam hydrochloride"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 713","initiation":"Initiation: 08/27/2018","start_date":" 08/27/2018","primary_txt":" Primary completion: 05/30/2028","primary_completion_date":" 05/30/2028","study_txt":" Completion: 05/30/2028","study_completion_date":" 05/30/2028","last_update_posted":"2025-02-07"},{"id":"45b9e4e8-9732-4ed9-b569-eae18917beb8","acronym":"KEYNOTE E27","url":"https://clinicaltrials.gov/study/NCT04956640","created_at":"2021-07-09T12:57:24.328Z","updated_at":"2025-02-25T16:16:26.190Z","phase":"Phase 1/2","brief_title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","source_id_and_acronym":"NCT04956640 - KEYNOTE E27","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-28"}]